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Inﬂammatory breast cancer (IBC) is a highly metastatic, lethal form of breast cancer that lacks targeted
therapeutic strategies. Inspired by the promising cytotoxicity of gambogic acid and related caged xan-
thones in spheroidsMARY-X, an in vitro preclinical IBC model, we constructed a library of synthetic analogs
and performed structure-activity relationship studies. The studies revealed that functionalizing the A-
ring of the caged xanthone framework can signiﬁcantly affect potency. Speciﬁcally, introduction of hy-
droxyl or ﬂuorine groups at discrete positions of the A-ring leads to enhanced cytotoxicity at sub-
micromolar concentrations. These compounds induce complete dissolution of spheroidsMARY-X with
subsequent apoptosis of both the peripherally- and centrally-located cells, proliferative and quiescent-
prone (e.g. hypoxic), respectively. These results highlight the structural ﬂexibility and pharmacological
potential of the caged xanthone motif for the design of IBC-targeting therapeutics.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Tropical trees of the genus Garcinia (Clusiaceae), grown mostly
in Southeast Asia, India, Africa and Brazil, are widely known not
only for their high value as sources of food but also for their role in
ethnomedicine [1e3]. For instance, gamboge, the dried resin from
Garcinia hanburyi, has been used in traditional Easternmedicine for
its anti-infective and anti-parasitic properties [4,5]. Efforts to
isolate the bioactive constituents of gamboge led to the identiﬁ-
cation of gambogic acid (GBA, 1) (Fig. 1), a caged xanthonoid that
displays potent anticancer activities both in vitro and in vivo [6e10]
and presents a promising therapeutic window for clinical.A. Theodoraki), alpaugh@
.A. Theodorakis).
served.applications [11e14]. In fact, GBA has entered clinical trials in China
for the treatment of non-small cell lung, colon and renal cancers
[15e17].
By virtue of its unusual chemical architecture, GBA has become
the archetype of a family of bioactive natural products that are
commonly referred to as caged xanthones (CXs) [18e21]. Several
members of this family exhibit potent activity against leukemia,
glioblastoma, lung cancer and colorectal cancer cell lines [22e24].
Central to their structure is a xanthone framework in which the C
ring has been converted into a caged motif. Plant-speciﬁc oxida-
tions and functionalizations of this framework contribute to the
structural diversity of this family. The pharmacological promise of
CXs has inspired several structure-function studies [25e30]. These
efforts unveiled that cluvenone (2, CLV) represents the minimum
pharmacophore of the CX family [31e33] and suggested that A-ring
functionalization could lead to analogs with improved bioactivity
[34e38]. Along these lines, MAD28 (3), the C6-hydroxylated clu-
venone, was found to be approximately 3 times more active than
MAD44 (4), the C18-hydroxylated cluvenone (Fig. 1), in inhibiting
Fig. 1. Chemical structures of representative caged xanthones: gambogic acid (GBA),
cluvenone (CLV), MAD28 and MAD44.
Scheme 1. Reagents and conditions: (a) 27 equiv. POCl3, 10 equiv. ZnCl2, 4.5 h, 65 C,
62%; (b) 3 equiv. Ph2CCl2, acetonitrile, MW, 12min, 150 C, 67%; (c) 2 equiv. MOMCl, 3
equiv. DIPEA, CH2Cl2, 1 h, 25 C, 100%; (d) H2, 10% Pd/C, THF/MeOH (3:1), 18 h, 25 C,
100%; (e) 10 equiv. t-butyl 2-methylbut-3-en-2-yl carbonate (9), 10mol% Pd(PPh3)4,
THF, 2 h, 0 C, 89%; (f) DMF, 4 h, 120 C, 69%; (g) 15% HCl, acetone, 24 h, 25 C, 32%.
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[39]. More recently, MAD28 (1.25 mM) was shown to exhibit se-
lective cytotoxicity against human epithelial breast cancer cells
(MDA-MB-231 or MCF7) with no apparent detrimental effect in
normal breast cells (MCF10A) [40].
The promising activity ofMAD28 against breast cancer led us to
evaluate its cytotoxicity in spheroidsMARY-X, a 3-dimensional
multicellular system formed from a patient-derived xenograft of
inﬂammatory breast cancer (IBC) [41]. IBC is a highly aggressive and
often lethal subtype of breast cancer accounting for about 3e10% of
diagnosed breast carcinomas [42e46]. Its high mortality rate is due
to its metastatic nature and triple negative signature that renders
IBC resistant to chemotherapeutic regimens [47e49]. Additionally,
IBC lacks molecular markers making diagnosis and design of tar-
geted therapeutic approaches very challenging. It is accepted that
the lymphovascular embolus is a marker of cancer aggressiveness,
recurrence, metastatic progression and therapeutic failure in many
tumor types [50e53]. The spheroidsMARY-X maintain the 3-
dimensional and pathophysiological features of the lymphovas-
cular embolus [54]. As such, they provide a relevant model to test
efﬁcacy of therapeutics to IBC andmetastatic disease in general. We
found that both GBA and MAD28 induce spheroid dissolution and
cell death in the spheroidsMARY-X assay with IC50 values of 0.42 and
0.66 mM, respectively [41]. Importantly, this activity was 20-fold
greater than that observed with taxol (IC50¼ 7.8 mM) while other
FDA-approved drugs failed to induce any response [41].
In this study, we synthesized and evaluated a library of caged
xanthones in which the A-ring has been chemically modiﬁed and
found that such functionalizations substantially modulate the
observed cytotoxicity in the spheroidsMARY-X assay. Notably,
attachment of electronwithdrawing groups at the A-ring as well as
introducing a free hydroxyl group at C6 enhances cytotoxicity and
results in complete dissolution with subsequent apoptosis of the
spheroidsMARY-X at submicromolar concentrations. Spatial/temporal
analysis of the multicellular IBC spheroid showed pyknotic nuclei
throughout as well as activation of PARP (i.e. cleaved PARP) at 3 h,
an indication of irreversible apoptosis. Fluorescent overlay analysis
of cPARP and the proliferation marker Ki67 indicated that these
compounds induce apoptosis irrespective of proliferation status.
Speciﬁcally, they target both the peripherally-located proliferative
cells as well as the centrally-located quiescent-prone (e.g. hypoxic)
cells of the multicellular spheroid. The latter represents the often
resistant and chemo-refractory cell population of this disease. Thus,
the caged xanthone motif represents a promising platform for
future preclinical development of IBC-targeted therapeutics.
2. Results and discussion
2.1. Synthesis of A-ring modiﬁed caged xanthones
The synthesis of the C6,C18-dihydroxylated caged xanthones 12and 13 is shown in Scheme 1. Condensation of phloroglucinol (5)
with 2,3,4-trihydroxybenzoic acid (6) under ZnCl2/POCl3 conditions
[55] produced a tetrahydroxylated xanthone that was subsequently
protected with diphenyldichloromethane to form compound 7
(42% yield over two steps) [56]. Selective protection of the more
reactive C18-phenol with MOMCl/DIPEA followed by deprotection
of the diphenyl ketal (H2, Pd/C) gave rise to xanthone 8 (100% yield
over two steps). Pd-catalyzed reverse prenylation of 8 with car-
bonate 9 [35] produced 10 in 89% yield. Heating of 10 in DMF at
120 C resulted in a site-selective Claisen rearrangement of the C12-
allyl ether to form intermediate 11 that underwent an intra-
molecular Diels-Alder cyclization to produce caged xanthone
MAD67 (12) (69% yield over two steps) [57]. Acid-catalyzed
deprotection of the C18-MOM group then gave rise to MAD69
(13) [37].
Treatment of 13 with tri(ethylene glycol) monomethyl ether
tosylate resulted in the formation of compounds 14 and 15 in var-
iable yields (Scheme 2) [58]. Monoalkylated compound 14 was
isolated as the only product when the reaction was performed at
room temperature, likely due to the higher reactivity of the C18
phenol. On the other hand, at 80 C the reaction gave rise to dia-
lkylated product 15 in 55% yield. Under similar conditions, caged
xanthones 3 and 4 [39] were converted to derivatives 16 and 17,
respectively.
The synthesis of the caged xanthones 23 and 25 is shown in
Scheme 3. Treatment of commercially available 2-ﬂuoro-1,4-
dimethoxybenzene (18) with n-BuLi and methyl chloroformate
Scheme 2. Reagents and conditions: 14: 1 equiv. 13, 2 equiv. K2CO3, 2 equiv. TsO(CH2-
CH2O)3Me, DMF, 8 h, 25 C, 75%; 15: 1 equiv. 13, 3 equiv. K2CO3, 3 equiv. TsO(CH2-
CH2O)3Me, DMF, 10 h, 80 C, 55%; 16: 1 equiv. 3, 2 equiv. K2CO3, 3 equiv.
TsO(CH2CH2O)3Me, DMF, 8 h, 25 C, 68%; 17: 1 equiv. 4, 2 equiv. K2CO3, 2 equiv.
TsO(CH2CH2O)3Me, DMF, 8 h, 80 C, 86%.
Scheme 3. Reagents and conditions: (a) 1.2 equiv. 1.6M n-BuLi, THF, 1 h, 78 C; then
1.2 equiv. ClCO2CH3, THF, 4 h, 78 C, 96%; (b) 5 equiv. LiOH, MeOH/H2O (3:1), 1.5 h,
70 C, 100%; (c) 1 equiv. pyrogallol (20), 27 equiv. POCl3, 10 equiv. ZnCl2, 2.5 h, 65 C,
40%; (d) 5 equiv. DIPEA, ACN, MW, 22min, 180 C, 74%; (e) 10 equiv. t-butyl 2-
methylbut-3-en-2-yl carbonate (9), 10mol% Pd(PPh3)4, THF, 24 h, 0 C, 77%; (f) DMF,
4 h, 120 C, 88%; (g) 1 equiv. BBr3 (1M in CH2Cl2), CH2Cl2, 2 h, 0 Ce25 C, 62%; (h) 10
equiv. t-butyl 2-methylbut-3-en-2-yl carbonate (9), 10mol% Pd(PPh3)4, THF, 18 h, 0 C,
63%; (i) DMF, 4 h, 120 C, 72%; (j) 1.2 equiv. PhI(OCOCF3)2, CH2Cl2, 1 h, 78 C to 30 C,
68%.
Scheme 4. Reagents and conditions: (a) 2 equiv. (COCl)2, DMF (cat.), CH2Cl2, 3 h,
0 Ce25 C, 100%; (b) 1 equiv. 20, 3 equiv. AlCl3, CHCl3/CH2Cl2 (1:2.5), 18 h, 25 C; then
24 h, 60 C, 81%; (c) 1 equiv. Na2CO3, DMF, 3 h, 90 C, 48%; (d) 10 equiv. bis(2-
methylbut-3-en-2-yl) carbonate (30), 10mol% Pd(PPh3)4, THF, 40min, 5 C, 100%; (e)
DMF, 1 h, 120 C, 64% for 32, 3% for 33.
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acid 19 (96% combined yield) [59]. A two-step condensation of 19
with pyrogallol (20) produced xanthone 21 in 30% combined yield.
This compound was subsequently allylated with 9 under Pd (0)
catalysis and the resulting adduct 22 was rearranged to caged
xanthone 23 via a Claisen/Diels-Alder reaction cascade. Various
conditions, e.g. PhI(OCOCF3)2 or cerium ammonium nitrate, were
evaluated for the in situ oxidative demethylation of 23 to 25 but
they proved to be unsuccessful [60]. To overcome this issue, we
sought to accomplish this conversion in two distinct steps [61,62].
Along these lines, we converted 21 to 25 via: (a) boron tribromide
induced demethylation of the C6 methyl ether; (b) Pd (0) mediated
allylation of the resulting xanthone with 9; (c) Claisen/Diels-Alder
rearrangement; and (d) PhI(OCOCF3)2-mediated oxidation of the
resulting caged xanthone 24 (19% combined yield).
The synthesis of A-ring ﬂuorinated caged xanthones is described
in Scheme 4. Xanthone 29 containing ﬂuorine at C6 and C18 wasprepared via: (a) conversion of 2,4,6-triﬂuoro benzoic acid (26) to
its acyl chloride 27; (b) Friedel-Crafts acylation of 27 with pyro-
gallol (20); and (c) intramolecular nucleophilic aromatic substitu-
tion of the resulting benzophenone 28 (39% combined yield,
Scheme 4). Pd (0)-catalyzed reverse prenylation of 29 with car-
bonate 30 gave xanthone 31. In the ﬁnal step, heat-induced Claisen/
Diels-Alder reaction cascade produced the regular caged xanthone
32 in 64% yield accompanied by a small amount of the neo cage
isomer 33 (3% yield).
2.2. Screening of caged xanthones using the spheroidsMARY-X assay
The activity of the synthetic caged xanthones was determined
using the spheroidsMARY-X assay. This system allows quick assess-
ment of the drug response via brightﬁeld microscopy and ImageJ
circularity analysis (see Fig. S1, Supplemental Information), where
spheroid dissolution is displayed as a deviation from the well-
circumscribed spheroid edge which correlates with induction of
apoptosis (i.e. drug response) [41,63]. Brieﬂy, 30e50 spheroidsMARY-
X were seeded in a multi-well plate and treated with increasing
doses of each compound or DMSO (vehicle) for 24 h. All the com-
pounds were tested at ﬁve different concentrations, ranging from
0.5 mM to 2.5 mM. CX analogs that showed no response (NR), low
response (LR) and moderate response (MR) at the highest con-
centration (2.5 mM) are presented in Fig. 2. MAD69 and CR240C
showed no response (NR) as there was no deviation of the well-
circumscribed edge of the spheroidsMARY-X comparable to the
vehicle only (DMSO, control) treated spheroidsMARY-X (Fig. S1).
Analogs MAD44 and P67 showed low response (LR) while CR140,
CR170B showed low to moderate response (LR-MR); both pairs of
drugs resulted in only minor deviations from the well-
circumscribed spheroid edge. In contrast, the extent of the devia-
tion was increased for spheroidsMARY-X treated with CR170A and
CR136 leading to a moderate response (MR).
Fig. 2. Screening of A-ring modiﬁed caged xanthones in spheroidsMARY-X. Brightﬁeld
images of spheroidsMARY-X after 24 h of treatment with 2.5 mM show a gradation of drug
response from no deviation (black arrowheads) from well-circumscribed spheroid
edge to an increase in deviation (blue arrowheads) and loss of well-circumscribed
spheroid edge, as follows: MAD69, CR240C: no response (NR); MAD44, P67: low
response (LR); CR140, CR170B: low response to moderate response (LR-MR); and
CR170A, CR136: moderate response (MR). (For interpretation of the references to color
in this ﬁgure legend, the reader is referred to the Web version of this article.)
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complete response (CR) as evidenced by a total dissolution of the
spheroidsMARY-X after 24 h treatment at 2.5 mM. Speciﬁcally,MAD28,
MAD67, CLV, RA25 and RA25N induced complete response (CR)
leading to a single cell suspension of the formerly intact, well-
circumscribed spheroidsMARY-X. These analogs were subjected to a
separate, more detailed screening, aiming to quantify their effect on
spheroidsMARY-X and determine their IC50 values. During this second
screening, nine concentrations from 0.25 mM to 2.25 mMat 0.25 mM
dose intervals of each compound were generated by serial dilutions
and were used to treat the spheroidsMARY-X for 24 h. The effect of
these compounds in four representative concentrations (0.5, 0.75,
1.0 and 2.0 mM) is shown in Fig. 3 (the entire 9-concentration panel
is shown in Supplemental Information; Fig. S2). The brightﬁeld
images acquired from this screening were further analyzed using
ImageJ software [64] in order to quantify the circularity/response of
the spheroidsMARY-X and construct a dose-response graph that al-
lows for calculation of IC50 values (Fig. 4).2.3. Structure-activity relationship study
Comparison of CLV (IC50¼ 0.63 mM) and MAD28
(IC50¼ 0.51 mM) indicates enhancement of cytotoxicity when there
is a free OH group at the C6 center of the A-ring of the CX scaffold
(Table 1). Alkylation of this group decreases the cytotoxicity as
shown with CR136 (MR) and also with P67 (LR). These results may
be due to an intramolecular hydrogen bonding between the C6-OH
and the near carbonyl group that, in turn, increases the electro-
philicity of the C10 enone. On the other hand, installation of a free
OH group at C18 substantially reduces the cytotoxicity as shown in
both MAD44 and MAD69 (LR and NR, respectively). In the latter
structure, even the presence of an OH group at C6 is not sufﬁcient to
induce cytotoxicity. Alkylating the free C18 phenol group partially
enhances the cytotoxicity as shown by comparing CR170B (LR-MR)
toMAD69 (NR) as well asMAD44 (LR) to CR140 (LR-MR). Moreover,
when the C18 phenol is alkylated, the presence of a free OH group
at the C6 center improves activity as shown by comparing CR170A
(MR) to CR170B (LR-MR). In fact, MAD67 that contains a MOM-
protected C18 phenol and a free C6 hydroxyl group induces com-
plete response (CR; i.e. leads to a single cell suspension of the
formerly intact, well-circumscribed spheroidsMARY-X) and has the
highest cytotoxicity (IC50¼ 0.38 mM).
Conversion of the A-ring phenol to a quinone leads to complete
loss of activity as shown with CR240C (NR) indicating that the A-
ring should maintain its aromatic character. On the other hand,replacement of hydrogens with ﬂuorines at the A-ring maintains
the CR phenotype but leads to a slight decrease of the cytotoxicity
as shown by comparing the diﬂuorinated analogs RA25
(IC50¼1.12 mM) and RA25N (IC50¼ 0.89 mM) to CLV
(IC50¼ 0.63 mM). The ﬁnding that both RA25 and RA25N induce
complete response (CR) and have similar cytotoxicity
(IC50¼1.12 mM and 0.89 mM, respectively) indicates that both
isomeric forms of the caged motif have comparable activity. Similar
observations have been reported when comparing other caged
xanthones that contain regular versus neo caged structures [65,66].
2.4. Evaluation of the spatial and temporal induction of apoptosis in
spheroidsMARY-X by selected caged xanthones
The spheroidsMARY-X is a spontaneously-forming 3-dimensional
model system that accurately recapitulates the growth, behavior
and microenvironment of solid tumors [67e72]. To investigate
whether the lead compounds can target any cell of themulticellular
spheroid or are restricted to targeting a speciﬁc cell subpopulation,
we evaluated the status of proliferation and apoptosis within the
spheroids using immunoﬂuorescence. For this experiment, the
spheroidsMARY-X were suspended in an extracellular matrix (ECM)
plug, which provides a scaffold that prevents dispersion of the cells
during drug treatment. The ECM plugs containing spheroidsMARY-X
were then exposed to 2.5 mM of MAD28, MAD67 and RA25, or
DMSO (control) and monitored using brightﬁeld microscopy for
loss of the well-circumscribed spheroid edge. Treatment was
terminated after 3 h, when deviations from the well-circumscribed
spheroid edge of all compound-treated spheroids were detected
(Fig. 5; brightﬁeld column, white arrowheads). The ECM plugs of
vehicle only (DMSO) and compound-treated samples were then
ﬁxed and stained with the nuclear stain, 40,6-diamidine-20-phe-
nylindole dihydrochloride (DAPI), and immunostained with the
apoptotic marker, cleaved fragment of poly (ADP-ribose) polymer-
ase (cPARP) and the proliferative marker Ki67 (Fig. 5). Spheroids
treated with vehicle only (DMSO) were found to have intact nuclei
(i.e. viable cells) as shown with DAPI staining in sections corre-
sponding to the middle of the spheroids. However, treatment for
3 h with 2.5 mM of MAD28, MAD67, and RA25 was sufﬁcient to
induce apoptosis, as shown by the appearance of pyknotic nuclei
(Fig. 5; DAPI column, white arrowheads). These pyknotic nuclei
correlate to the loss of well-circumscribed edges in all three
compound-treated samples (Fig. 5; brightﬁeld column, white
arrowhead). Pyknotic nuclei were detected both in cells on the
periphery and the center of the spheroid. This indicates that not
only can the compounds effectively target the peripherally-located
proliferative cells but also the centrally-located, quiescent-prone
cells of the spheroids. Detection of cPARP after treatment with all
three compounds, suggests that 3 h of treatment at 2.5 mM is
adequate to activate caspases and irreversible initiation of
apoptosis throughout the spheroid (Fig. 5; cPARP column). Staining
with Ki-67, a commonly used proliferation marker, and ﬂuorescent
overlay analysis (i.e. induction of apoptosis vs. proliferation status)
shows that MAD28, MAD67 and RA25 target all cells of the
multicellular spheroid and thus are efﬁcacious irrespective of
proliferation status (Fig. 5; Ki67 column). This impartial cancer cell
targeting is clearly advantageous over the effect of various FDA-
approved anticancer drugs that mainly target proliferating cells
[40,41,73,74].
3. Conclusions
We report here the synthesis of a library of caged xanthones and
their in vitro evaluation in spheroidsMARY-X, a preclinical model of
inﬂammatory breast cancer. The synthetic strategy starts with acid-
Fig. 3. Dose-dependent response of spheroidsMARY-X upon treatment with MAD28, CLV, MAD67, RA25 and RA25N. Representative brightﬁeld images of spheroidsMARY-X 24 h post
drug treatment at 0.5, 0.75, 1.0 and 2.0 mM concentrations (bar 100 mm).
Fig. 4. Dose-response curves and IC50 values of CX analogs inducing complete
response. Circularity values obtained via ImageJ analysis were used to calculate the
IC50 values for MAD28, MAD67, CLV, RA25 and RA25N. The non-linear ﬁt curves and
calculation of IC50 value for each analog were performed using GraphPad Prism.
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matic rings to form the central xanthone motif that is then con-
verted to the caged structure using the Claisen Diels-Alder reaction
cascade. The overall strategy proceeds in 5e6 steps and delivers A-
ringmodiﬁed analogs in good yields. Structure-activity relationship
studies reveal that the cytotoxicity in the spheroidsMARY-X assay can
be regulated by selective functionalization of the A-ring. Notably,
introduction of a free hydroxyl group at the C6 position leads tocompounds that exhibit complete response in the spheroid assay at
low micromolar concentrations. Speciﬁcally, MAD28 and MAD67
were found to induce complete dissolution of the spheroids with
IC50 values of 0.51 and 0.38 mM, respectively. Conversely, intro-
duction of a free hydroxyl group at C18 as well as further oxidation
of the A-ring leads to a decrease in cytotoxicity as evidenced with
MAD44, MAD69, CR240C and related structures. Exchange of
hydrogen atoms with ﬂuorines at the A-ring leads to compounds
RA25 and RA25N that maintain the complete response phenotype
albeit at a slight increase of the effective concentration (IC50 values
1.12 and 0.89 mM, respectively). Additional studies in ECM-
immobilized spheroids showed that MAD28, MAD67 and RA25
effectively target both proliferative (peripherally located) and
quiescent-prone (centrally located) cells of the multicellular
spheroid. Therefore, these compounds hold promise for the treat-
ment of resistant and chemo-refractory quiescent cancer cells [75].
Overall, these ﬁndings can be used to accelerate and streamline the
development of IBC-based therapeutics based on the caged
xanthone pharmacophore.
4. Experimental section
General information for chemical puriﬁcation and com-
pounds characterization. Reactions were monitored by thin-layer
chromatography (TLC) carried out on 0.25mmE. Merck silica gel
plates (60F-254) and visualized under UV light and/or by treatment
with a solution of CAM or KMnO4 stain followed by heating. Pre-
parative thin-layer chromatography separations were carried out
on 0.25 or 0.50mmE. Merck silica gel plates (60F-254). Flash
Table 1
SAR data of CX analogs.
CX analogs R1 R2 Response IC50 (mM)
CLV H H CR 0.63
MAD28 OH H CR 0.51
MAD44 H OH LR
MAD67 OH OMOM CR 0.38
MAD69 OH OH NR
CR170A OH O(CH2CH2O)3Me MR
CR170B O(CH2CH2O)3Me O(CH2CH2O)3Me LR-MR
CR136 O(CH2CH2O)3Me H MR
CR140 H O(CH2CH2O)3Me LR-MR
P67 OMe OMea LR
CR240C C¼O C¼Oa NR
RA25 F F CR 1.12
RA25Nb F F CR 0.89
a R2 is located at the C17 center.
b RA25N contains a neo caged motif.
Fig. 5. Analysis of induction of apoptosis in spheroidsMARY-X after 3 h of treatment with MAD28, MAD67 and RA25 at 2.5 mM. Brightﬁeld microscopy panels show the loss of well-
circumscribed spheroid edge upon treatment in comparison to the control (DMSO). The immunoﬂuorescence microscopy panels show optical slices from the middle of the
spheroidsMARY-X and present DAPI stained nuclei (pyknotic nuclei indicated by arrowheads), localization of c-PARP, Ki-67 and the merged pictures. (bar 20 mm).
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selgel 60, 230e400 mesh) using hexane/ethyl acetate or hexane/
ethyl ether as standard eluents. 1H NMR and 13C NMR spectra were
recorded on a 400 or 500MHz Varian or a 500 JEOL instrument.
Chemical shifts (d) are quoted in parts per million (ppm) referenced
to the appropriate residual undeuterated solvent peak, with the
abbreviations s, bs, d, t, q, dd, m, denoting singlet, broad singlet,
doublet, triplet, quartet, doublet of doublets, multiplet, respec-
tively. J is a coupling constant given in Hertz (Hz). High resolution
mass spectra (HRMS) were recorded on a VG7070HS mass spec-
trometer under chemical ionization (CI) conditions, on a VG ZAB-
ZSE mass spectrometer under fast atom bombardment (FAB) con-
ditions, or on a Bruker microTOF mass spectrometer under elec-
trospray ionization (ESI) conditions. Speciﬁc information on thesynthetic/analytical protocols as well as copies of the spectroscopic
data for all compounds are shown in the Supporting Information.
General procedure for Pd(0)-catalyzed reverse prenylation. A
solution of starting xanthone (1 equiv) in anhydrous THF
(approximate 0.2mM) was degassed by argon and was placed in an
ice bath. To this homogeneous solution was added tert-butyl 2-
methylbut-3-en-2-yl carbonate (9) or bis(2-methylbut-3-en-2-yl)
carbonate (30) (10 equiv) via syringe, followed by 10% mol
Pd(PPh3)4. The mixture was stirred under argon at 0e5 C and the
reaction progress was monitored by TLC. Upon completion the re-
actionmixturewas quenchedwith water and extractedwith EtOAc.
The combined organic layers were dried over MgSO4, ﬁltered and
concentrated by rotary evaporation. The crude material was puri-
ﬁed through ﬂash column chromatography (silica, EtOAc in hexane)
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1-hydroxy-3-(methoxymethoxy)-5,6-bis((2-methylbut-3-en-
2-yl)oxy)-9H-xanthen-9-one (10): 89%, a colorless oil. Rf¼ 0.57
(25% EtOAcehexane); 1H NMR (400MHz, CDCl3) d 7.82 (d,
J¼ 9.0 Hz, 1H), 7.11 (d, J¼ 9.0 Hz, 1H), 6.56 (d, J¼ 2.2 Hz, 1H), 6.46
(d, J¼ 2.2 Hz, 1H), 6.29e6.14 (m, 2H), 5.25 (s, 2H), 5.21e5.15 (m,
3H), 5.03 (d, J¼ 10.9 Hz, 1H), 3.51 (s, 3H), 1.57 (s, 9H), 1.57 (s, 3H);
13C NMR (100MHz, CDCl3) d 180.9, 164.0, 163.5, 157.5, 152.5, 143.7,
143.5, 120.4, 116.8, 114.4, 113.4, 98.8, 94.9, 94.4, 83.9, 82.5, 56.7, 27.4,
27.1; HRMS calc. for C25H29O7 (M þ H)þ 441.1988, found 441.1907.
1,4-dimethoxy-5,6-bis((2-methylbut-3-en-2-yl)oxy)-9H-
xanthen-9-one (22): 77%, a colorless oil. Rf¼ 0.43 (50%
EtOAcehexane); 1H NMR (400MHz, CDCl3) d 7.87 (d, J¼ 9.1 Hz,1H),
7.15 (d, J¼ 8.9 Hz,1H), 7.08 (d, J¼ 9.0 Hz,1H), 6.69 (d, J¼ 9.0 Hz,1H),
6.41 (dd, J¼ 10.7, 17.6 Hz, 1H), 6.19 (dd, J¼ 10.8, 17.6 Hz, 1H),
5.21e5.13 (m, 3H), 4.97 (d, J¼ 10.9 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H),
1.61 (s, 6H), 1.55 (s, 6H); 13C NMR (100MHz, CDCl3) d 176.4, 156.2,
153.6,151.2, 148.0, 143.8, 143.7,142.6,135.8, 120.8, 117.2, 116.2,113.9,
113.0, 104.2, 83.9, 82.0, 56.7, 56.5, 27.1, 26.7; HRMS calc. for
C25H28O6Na (M þ Na)þ, 447.1778 found 447.1777.
1,3-diﬂuoro-5,6-bis((2-methylbut-3-en-2-yl)oxy)-9H-
xanthen-9-one (31): 100%, a colorless oil. Rf¼ 0.56 (33%
Et2Oehexane); 1H NMR (400MHz, CDCl3) d 7.87 (d, J¼ 9.1 Hz, 1H),
7.13 (d, J¼ 9.0 Hz, 1H), 6.97 (d, JH,F¼ 9.1 Hz, 1H), 6.78 (t,
JH,F¼ 10.9 Hz, 1H), 6.27e6.13 (m, 2H), 5.23e5.16 (m, 3H), 5.04 (d,
J¼ 10.8 Hz, 1H), 1.57 (s, 6H), 1.56 (s, 6H); 13C NMR (100MHz, CDCl3)
d 174.3, 166.8 (d, JC,F¼ 15.4 Hz), 164.3 (dd, JC,F¼ 15.0, 8.1 Hz), 161.7
(d, JC,F¼ 15.6 Hz), 158.0 (d, JC,F¼ 15.9 Hz), 157.4, 151.8, 143.7, 143.5,
135.4, 121.3, 117.2, 114.5, 113.4, 101.1 (d, JC,F¼ 25.1 Hz), 101.0 (t,
JC,F¼ 24.2 Hz), 84.0, 82.6, 27.4, 27.2; HRMS calc. for C23H22F2O4Na
(M þ Na)þ 423.1378, found 423.1377.
General procedure for Claisen/Diels-Alder reaction. A solution
of allylated compound (1 equiv) in DMF was heated at 120 C. The
onset of a yellow color indicated the formation of the caged
xanthone. The reaction progress was monitored by TLC. Upon
completion, the yellow reaction mixture was cooled to room tem-
perature and the solvent was removed under vacuum by rotary
evaporation. The crude material was puriﬁed by ﬂash column
chromatography (silica, EtOAc or Et2O in hexane) to yield the caged
xanthone.
8-hydroxy-10-(methoxymethoxy)-2,2-dimethyl-3a-(3-
methylbut-2-en-1-yl)-1,2-dihydro-1,5-methanofuro[2,3-d]xan-
thene-4,7(3aH,5H)-dione (12): 69%, yellow solid. Rf¼ 0.24 (25%
EtOAcehexane); 1H NMR (400MHz, CDCl3) d 12.38 (s, 1H), 7.43 (d,
J¼ 7.1 Hz, 1H), 6.20 (d, J¼ 2.1 Hz, 1H), 6.17 (d, J¼ 2.1 Hz, 1H), 5.19 (s,
2H), 4.45e4.41 (m, 1H), 3.51e3.48 (m, 1H), 3.47 (s, 3H), 2.61 (d,
J¼ 8.8 Hz, 2H), 2.43 (d, J¼ 9.6 Hz, 1H), 2.33 (dd, J¼ 13.6, 4.7 Hz, 1H),
1.68 (s, 3H), 1.38 (s, 3H), 1.32e1.31 (m, 1H), 1.29 (s, 3H), 1.09 (s, 3H);
13C NMR (100MHz, CDCl3) d 203.2, 179.7, 166.1, 164.9, 161.1, 135.4,
134.2, 133.9, 118.5, 101.8, 97.2, 95.7, 94.1, 90.4, 84.6, 83.7, 56.7, 49.0,
47.0, 30.6, 29.9, 29.3, 25.8, 25.3, 17.0; HRMS calc. for C25H28O7Na
(M þ Na)þ 463.1727, found 463.1729.
8,11-dimethoxy-2,2-dimethyl-3a-(3-methylbut-2-en-1-yl)-
1,2-dihydro-1,5-methanofuro[2,3-d]xanthene-4,7(3aH,5H)-
dione (23): 88%, yellow solid. Rf¼ 0.40 (50% EtOAcehexane); 1H
NMR (400MHz, CDCl3) d 7.31 (d, J¼ 6.9 Hz, 1H), 7.04 (d, J¼ 9.0 Hz,
1H), 6.47 (d, J¼ 9.0 Hz, 1H), 4.52 (t, J¼ 7.9 Hz, 1H), 3.88 (s, 3H), 3.85
(s, 3H), 3.44 (dd, J¼ 7.0, 4.2 Hz 1H), 2.61 (d, J¼ 9.0 Hz, 2H), 2.40 (d,
J¼ 9.6 Hz, 1H), 2.32 (dd, J¼ 13.5, 4.6 Hz, 1H), 1.78 (s, 3H), 1.39 (s,
3H), 1.30 (s, 3H), 1.30e1.27 (m, 1H), 1.09 (s, 3H); 13C NMR (100MHz,
CDCl3) d 203.3, 176.1, 154.3, 151.2, 143.0, 136.4, 132.5, 118.7, 118.5,
110.9, 102.8, 90.0, 84.5, 83.6, 57.0, 56.4, 48.5, 46.7, 29.5, 29.1, 29.0,
25.6, 25.4, 16.9; HRMS calc. for C25H28O6Na (M þ Na)þ, 447.1778
found 447.1776.
8-hydroxy-11-methoxy-2,2-dimethyl-3a-(3-methylbut-2-en-1-yl)-1,2-dihydro-1,5-methanofuro[2,3-d]xanthene-
4,7(3aH,5H)-dione (24): 72%, yellow solid. Rf¼ 0.50 (50%
EtOAcehexane); 1H NMR (400MHz, CDCl3) d 11.55 (s, 1H), 7.49 (d,
J¼ 7.0 Hz, 1H), 7.12 (dd, J¼ 8.9, 1.8 Hz, 1H), 6.47 (dd, J¼ 8.9, 1.8 Hz,
1H), 4.43e4.39 (m, 1H), 3.84 (s, 3H), 3.55e3.52 (m, 1H), 2.64 (d,
J¼ 9.5 Hz, 2H), 2.47 (d, J¼ 9.6 Hz, 1H), 2.36 (dd, J¼ 13.6, 4.2 Hz, 1H),
1.78 (s, 3H), 1.36 (s, 3H), 1.31 (s, 4H),1.00 (s, 3H); 13C NMR (100MHz,
CDCl3) d 202.8, 181.6, 156.2, 149.5, 140.7, 135.4, 135.0, 134.0, 124.1,
119.0, 107.6, 106.5, 90.4, 84.7, 84.0, 57.9, 49.0, 47.1, 29.8, 29.4, 29.3,
25.7, 24.9, 16.8; HRMS calcd for [C24H26O6Na]þ (M þ Na)þ
433.1622, found 433.1623.
8,10-diﬂuoro-2,2-dimethyl-3a-(3-methylbut-2-en-1-yl)-1,2-
dihydro-1,5-methanofuro[2,3-d]xanthene-4,7(3aH,5H)-dione
(32): 64% yellow solid; Rf¼ 0.38 (50% Et2Oehexane); 1H NMR
(400MHz, CDCl3) d 7.42 (d, J¼ 6.9 Hz, 1H), 6.60 (d, JH,F¼ 9.5 Hz,
1H), 6.53 (t, JH,F¼ 10.9 Hz, 1H), 4.46 (t, J¼ 6.9 Hz, 1H), 3.52e3.49
(m, 1H), 2.60 (d, J¼ 8.3 Hz, 2H), 2.44 (d, J¼ 10.0 Hz, 1H), 2.34 (dd,
J¼ 13.6, 4.6 Hz, 1H), 1.67 (s, 3H), 1.40 (s, 3H), 1.35e1.31 (m, 1H), 1.30
(s, 3H), 1.09 (s, 3H); 13C NMR (100MHz, CDCl3) d 202.7, 173.5, 168.2
(d, JC,F¼ 16.0 Hz), 165.3 (dd, JC,F¼ 77.3, 15.9 Hz), 162.2 (d,
JC,F¼ 16.0 Hz), 161.8 (dd, JC,F¼ 15.6, 5.5 Hz), 135.2, 134.7, 134.5,
118.9, 101.5 (dd, JC,F¼ 24.6, 4.4 Hz), 99.4 (t, JC,F¼ 25.5 Hz), 91.4,
84.6, 83.7, 49.0, 47.0, 29.9, 29.3, 29.2, 25.7, 25.5, 17.2; HRMS calc. for
C23H22F2O4Na (M þ Na)þ 423.1378, found 423.1373.
6,8-diﬂuoro-2,2-dimethyl-11a-(3-methylbut-2-en-1-yl)-
2,3,3a,11a-tetrahydro-3,10a-methanofuro[3,2-b]xanthene-5,11-
dione (33): 3%, yellow solid; Rf¼ 0.48 (50% Et2Oehexane); 1H NMR
(400MHz, CDCl3) d 7.22 (d, J¼ 7.0 Hz,1H), 6.74 (d, JH,F¼ 9.6 Hz,1H),
6.52 (t, JH,F¼ 11.0 Hz, 1H), 5.01 (t, J¼ 6.9 Hz, 1H), 3.76 (dd, J¼ 6.9,
4.7 Hz, 1H), 2.50e2.46 (m, 2H), 2.19 (dd, J¼ 9.9, 4.5 Hz, 1H),
2.12e2.04 (m,1H),1.87 (dd, J¼ 13.2,10.0 Hz,1H),1.72 (s, 3H),1.60 (s,
3H), 1.38 (s, 3H), 1.35 (s, 3H); 13C NMR (100MHz, CDCl3) d 199.6,
172.8, 168.5 (d, JC,F¼ 15.8 Hz), 165.9 (d, JC,F¼ 16.1 Hz), 162.7 (m),
162.2 (m), 136.7, 135.6, 131.8, 117.4, 102.0 (dd, JC,F¼ 24.9, 4.2 Hz),
99.7 (t, JC,F¼ 20.0 Hz), 85.0, 84.1, 79.2, 44.9, 42.5, 32.9, 30.3, 29.8,
26.9, 26.1, 18.4; HRMS calc. for C23H22F2O4Na (M þ Na)þ 423.1378,
found 423.1379.
Culture of spheroidsMARY-X. The spheroidsMARY-X were cultured
in Minimal Essential Medium (MEM) supplemented with 10% heat-
inactivated fetal bovine serum and antibiotics (100 U/ml penicillin
and 100 mg/ml streptomycin) at 37 C in an air5% CO2 atmosphere
at constant humidity.
Compound screening and drug response using the spher-
oidsMARY-X assay. SpheroidsMARY-X ranging in size from 40 to
100 mm were seeded at a density of 30e50 spheroids/well in a
multi-well plate and treated in replicates with different drug con-
centrations or vehicle only (DMSO) as a control. Brightﬁeld images
were acquired 24 h post treatment and the response to the drugs
was evaluated based on deviations from the circularity of intact,
well-circumscribed spheroidsMARYX. Circularity measurements for
compounds that led to complete dissolution, turning the
spheroidsMARYX to single cell suspension were obtained using
ImageJ. The parameters of the image analysis are set so that ‘1’
indicates a perfect circle (i.e. intact spheroid; no response) and
numbers approaching ‘0’ indicate loss of circularity (i.e. dissolute
spheroid; response). Response to drug treatment is ranked as no
response, low response, moderate response or complete response,
based on the degree of deviation from a well-circumscribed
spheroid edge. The circularity measurements were then trans-
ferred into GraphPad Prism v. 7.04 in order to construct a dose-
response curve and calculate the IC50 values of each drug.
Immunoﬂuorescence in extracellular matrix plugs. Extracel-
lular matrix (Matrigel; Corning LifeSciences, cat.# 356237) was
thawed at 4 C overnight and kept on ice at all times during use. A
mixture of matrigel with spheroidsMARY-X in media at a 2:1 ratiowas
O. Chantarasriwong et al. / European Journal of Medicinal Chemistry 168 (2019) 405e413412prepared and added on top of a glass coverslip into each well of a
plate. The plate with the matrigel plugs was allowed to solidify for
30min at 37 C, before adding media with appropriate drug con-
centrations in the wells. After 3 h of treatment, the drug containing
media was removed and the wells were topped off with 4% para-
formaldehyde (PFA). PFA ﬁxation proceeded for 30min at room
temperature, followed by PBS washes and 15min permeabilization
of the cells with 2% Triton X-100 in PBS. After washing twice with
1 PBS, the cells were blocked with 3% normal goat serum in 1
PBS for 30min at room temperature. The treated cells inside the
Matrigel plug were then incubated at 4 C for 24 h with Alexa Fluor
488 conjugated anti-Ki67 (BD Pharmingen, #558616) and cPARP
(Promega, #G7341) at 1:10 and 1:100, respectively. Incubationwith
Cy5 conjugated goat anti-rabbit (Invitrogen, A10523) secondary at
4 mg/ml followed at 4 C for 24 h. After three washes in 1 PBS, a
drop of Vectashield mounting medium with DAPI (Vector Labora-
tories, H-1200) was applied on top of the Matrigel plugs with the
treated cells and then the coverslips were ﬂipped and sealed on
slides. The slides were visualized and subjected to z-stacking using
a Zeiss AxioObserver Z1 with ApoTome2 inverted microscope.
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